Benjamin Burnett
Stock Analyst at Wells Fargo
(3.81)
# 669
Out of 5,148 analysts
96
Total ratings
55.56%
Success rate
8.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $21.01 | +42.79% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $30.25 | +42.15% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $166.38 | +21.41% | 4 | Feb 24, 2026 | |
| INSM Insmed | Maintains: Overweight | $234 → $208 | $146.32 | +42.15% | 2 | Feb 20, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $26.51 | +32.03% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.50 | +100.00% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $60.77 | -19.37% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $114.05 | +6.97% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $28.69 | +140.50% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $33.04 | +105.81% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.65 | +73.58% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $4.91 | +1,071.08% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $4.33 | +17,913.86% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $49 | $42.55 | +15.16% | 4 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $3.04 | +130.64% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $423 → $466 | $513.82 | -9.31% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $330.59 | -7.74% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $66.37 | +29.58% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $13.85 | +94.95% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $28.37 | +51.57% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $23.02 | +95.48% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $6.01 | +49.75% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $13.91 | +65.35% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $101.62 | -37.02% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $66.54 | +41.27% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.62 | +176.24% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.79 | +559.63% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $68.36 | +426.62% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.43 | +3,621.80% | 1 | Jan 6, 2021 |
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $21.01
Upside: +42.79%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $30.25
Upside: +42.15%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $166.38
Upside: +21.41%
Insmed
Feb 20, 2026
Maintains: Overweight
Price Target: $234 → $208
Current: $146.32
Upside: +42.15%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $26.51
Upside: +32.03%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.50
Upside: +100.00%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $60.77
Upside: -19.37%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $114.05
Upside: +6.97%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $28.69
Upside: +140.50%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $33.04
Upside: +105.81%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.65
Upside: +73.58%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $4.91
Upside: +1,071.08%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $4.33
Upside: +17,913.86%
Feb 27, 2026
Maintains: Overweight
Price Target: $48 → $49
Current: $42.55
Upside: +15.16%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $3.04
Upside: +130.64%
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $423 → $466
Current: $513.82
Upside: -9.31%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $330.59
Upside: -7.74%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $66.37
Upside: +29.58%
Feb 12, 2026
Maintains: Overweight
Price Target: $29 → $27
Current: $13.85
Upside: +94.95%
Feb 2, 2026
Initiates: Overweight
Price Target: $43
Current: $28.37
Upside: +51.57%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $23.02
Upside: +95.48%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $6.01
Upside: +49.75%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $13.91
Upside: +65.35%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $101.62
Upside: -37.02%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $66.54
Upside: +41.27%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.62
Upside: +176.24%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.79
Upside: +559.63%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $68.36
Upside: +426.62%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.43
Upside: +3,621.80%